Andy J. Schwab
Founder and Managing Partner

Prior to founding 5AM Ventures in 2002, Andy was a Principal at Bay City Capital.  After joining Bay City Capital in 1999, Andy led the firm's investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx. Prior to joining BCC, Andy was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and serves on the Board of Directors of  Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics, Synosia Therapeutics, Anaphore and TiVaMed. Andy received a BS with Honors in Genetics & Ethics from Davidson College and is currently a member of the Davidson Alumni Association Board.